10q10k10q10k.net

vs

Side-by-side financial comparison of Deere & Company (DE) and Pfizer (PFE). Click either name above to swap in a different company.

Pfizer is the larger business by last-quarter revenue ($17.6B vs $12.4B, roughly 1.4× Deere & Company). Deere & Company runs the higher net margin — 8.6% vs -9.4%, a 18.0% gap on every dollar of revenue. On growth, Deere & Company posted the faster year-over-year revenue change (11.2% vs -1.2%). Pfizer produced more free cash flow last quarter ($4.5B vs $3.5B). Over the past eight quarters, Pfizer's revenue compounded faster (8.6% CAGR vs 0.9%).

Deere & Company

Deere & CompanyDEEarnings & Financial Report

NYSE · Industrials · Agricultural & Farm Machinery

Deere & Company, doing business as John Deere, is an American corporation that manufactures agricultural machinery, heavy equipment, forestry machinery, diesel engines, drivetrains used in heavy equipment and lawn care equipment. It also provides financial services and other related activities.

Pfizer

PfizerPFEEarnings & Financial Report

NYSE · Health Care · Pharmaceuticals

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer (1824–1906) and Charles F. Erhart (1821–1891), Pfizer is one of the oldest pharmaceutical companies in North America.

DE vs PFE — Head-to-Head

Bigger by revenue
PFE
PFE
1.4× larger
PFE
$17.6B
$12.4B
DE
Growing faster (revenue YoY)
DE
DE
+12.4% gap
DE
11.2%
-1.2%
PFE
Higher net margin
DE
DE
18.0% more per $
DE
8.6%
-9.4%
PFE
More free cash flow
PFE
PFE
$1.0B more FCF
PFE
$4.5B
$3.5B
DE
Faster 2-yr revenue CAGR
PFE
PFE
Annualised
PFE
8.6%
0.9%
DE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DE
DE
PFE
PFE
Revenue
$12.4B
$17.6B
Net Profit
$1.1B
$-1.6B
Gross Margin
—
70.0%
Operating Margin
11.5%
-9.4%
Net Margin
8.6%
-9.4%
Revenue YoY
11.2%
-1.2%
Net Profit YoY
-14.5%
-501.7%
EPS (diluted)
$3.92
$-0.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DE
DE
PFE
PFE
Q4 25
$12.4B
$17.6B
Q3 25
$12.0B
$16.7B
Q2 25
$12.8B
$14.7B
Q1 25
$8.5B
$13.7B
Q4 24
$11.1B
$17.8B
Q3 24
$13.2B
$17.7B
Q2 24
$15.2B
$13.3B
Q1 24
$12.2B
$14.9B
Net Profit
DE
DE
PFE
PFE
Q4 25
$1.1B
$-1.6B
Q3 25
$1.3B
$3.5B
Q2 25
$1.8B
$2.9B
Q1 25
$869.0M
$3.0B
Q4 24
$1.2B
$410.0M
Q3 24
$1.7B
$4.5B
Q2 24
$2.4B
$41.0M
Q1 24
$1.8B
$3.1B
Gross Margin
DE
DE
PFE
PFE
Q4 25
—
70.0%
Q3 25
—
74.9%
Q2 25
—
74.2%
Q1 25
—
79.3%
Q4 24
—
66.7%
Q3 24
—
70.3%
Q2 24
—
75.2%
Q1 24
—
77.3%
Operating Margin
DE
DE
PFE
PFE
Q4 25
11.5%
-9.4%
Q3 25
13.3%
20.0%
Q2 25
18.3%
20.8%
Q1 25
10.5%
20.3%
Q4 24
13.6%
-0.1%
Q3 24
17.9%
26.6%
Q2 24
20.5%
-0.8%
Q1 24
18.2%
23.0%
Net Margin
DE
DE
PFE
PFE
Q4 25
8.6%
-9.4%
Q3 25
10.7%
21.3%
Q2 25
14.1%
19.9%
Q1 25
10.2%
21.6%
Q4 24
11.2%
2.3%
Q3 24
13.2%
25.2%
Q2 24
15.6%
0.3%
Q1 24
14.4%
20.9%
EPS (diluted)
DE
DE
PFE
PFE
Q4 25
$3.92
$-0.29
Q3 25
$4.75
$0.62
Q2 25
$6.64
$0.51
Q1 25
$3.19
$0.52
Q4 24
$4.57
$0.07
Q3 24
$6.29
$0.78
Q2 24
$8.53
$0.01
Q1 24
$6.23
$0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DE
DE
PFE
PFE
Cash + ST InvestmentsLiquidity on hand
$8.3B
$1.1B
Total DebtLower is stronger
—
—
Stockholders' EquityBook value
$25.9B
$86.5B
Total Assets
$106.0B
$208.2B
Debt / EquityLower = less leverage
—
—

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DE
DE
PFE
PFE
Q4 25
$8.3B
$1.1B
Q3 25
$8.6B
$1.3B
Q2 25
$8.0B
$1.6B
Q1 25
$6.6B
$1.4B
Q4 24
$7.3B
$1.0B
Q3 24
$7.0B
$1.1B
Q2 24
$5.6B
$1.1B
Q1 24
$5.1B
$719.0M
Stockholders' Equity
DE
DE
PFE
PFE
Q4 25
$25.9B
$86.5B
Q3 25
$25.2B
$92.8B
Q2 25
$24.3B
$88.7B
Q1 25
$22.5B
$90.3B
Q4 24
$22.8B
$88.2B
Q3 24
$23.1B
$92.3B
Q2 24
$22.7B
$87.7B
Q1 24
$22.1B
$92.3B
Total Assets
DE
DE
PFE
PFE
Q4 25
$106.0B
$208.2B
Q3 25
$107.8B
$208.7B
Q2 25
$106.3B
$206.1B
Q1 25
$103.1B
$208.0B
Q4 24
$107.3B
$213.4B
Q3 24
$107.8B
$219.5B
Q2 24
$105.6B
$216.2B
Q1 24
$101.4B
$221.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DE
DE
PFE
PFE
Operating Cash FlowLast quarter
$4.0B
$5.3B
Free Cash FlowOCF − Capex
$3.5B
$4.5B
FCF MarginFCF / Revenue
28.1%
25.6%
Capex IntensityCapex / Revenue
4.1%
4.8%
Cash ConversionOCF / Net Profit
3.75×
—
TTM Free Cash FlowTrailing 4 quarters
$6.1B
$9.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DE
DE
PFE
PFE
Q4 25
$4.0B
$5.3B
Q3 25
$2.9B
$4.6B
Q2 25
$1.7B
$-582.0M
Q1 25
$-1.1B
$2.3B
Q4 24
$5.1B
$6.7B
Q3 24
$3.2B
$6.7B
Q2 24
$1.9B
$-1.8B
Q1 24
$-908.0M
$1.1B
Free Cash Flow
DE
DE
PFE
PFE
Q4 25
$3.5B
$4.5B
Q3 25
$2.6B
$4.0B
Q2 25
$1.5B
$-1.2B
Q1 25
$-1.5B
$1.8B
Q4 24
$4.5B
$5.8B
Q3 24
$2.9B
$6.1B
Q2 24
$1.5B
$-2.4B
Q1 24
$-1.3B
$386.0M
FCF Margin
DE
DE
PFE
PFE
Q4 25
28.1%
25.6%
Q3 25
21.6%
24.0%
Q2 25
11.7%
-8.2%
Q1 25
-17.4%
12.9%
Q4 24
40.3%
32.7%
Q3 24
21.8%
34.3%
Q2 24
9.8%
-18.2%
Q1 24
-10.4%
2.6%
Capex Intensity
DE
DE
PFE
PFE
Q4 25
4.1%
4.8%
Q3 25
2.5%
3.6%
Q2 25
1.6%
4.2%
Q1 25
4.1%
4.1%
Q4 24
5.4%
5.2%
Q3 24
2.5%
3.7%
Q2 24
2.3%
4.8%
Q1 24
3.0%
4.7%
Cash Conversion
DE
DE
PFE
PFE
Q4 25
3.75×
—
Q3 25
2.25×
1.30×
Q2 25
0.94×
-0.20×
Q1 25
-1.30×
0.79×
Q4 24
4.09×
16.39×
Q3 24
1.84×
1.50×
Q2 24
0.78×
-43.44×
Q1 24
-0.52×
0.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DE
DE

Production And Precision Agriculture Segment$2.0B16%
Construction And Forestry Segment$2.0B16%
Small Agriculture$1.8B15%
Financial Service$1.5B12%
Construction Equipment$1.4B11%
Small Agriculture And Turf Segment$1.2B9%
Roadbuilding$994.0M8%
Compact Construction Equipment$564.0M5%
Forestry$352.0M3%
Other$300.0M2%
Other Products And Services$146.0M1%
Financial Products$80.0M1%

PFE
PFE

U.S.Commercial Division$9.0B51%
Specialty Care$4.8B27%
Total Alliance Biopharmaceuticals$2.6B15%
Royalty$480.0M3%
Pfizer Centre One$409.0M2%

Related Comparisons

← Back to DE overview← Back to PFE overview